Share-Based Compensation

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

The Company has various stock compensation plans, which are more fully described in Part II, Item 8 “Financial Statements and Supplementary Data—Note 13 to the Consolidated Financial Statements—Equity-Based Compensation” in the Company’s 2023 Annual Report on Form 10-K. Under the Beauty Health Company 2021 Incentive Award Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalents, other stock or cash-based awards to eligible service providers. Additionally, the Company maintains the Employee Stock Purchase Plan for employees located in the United States, whereby eligible employees can have up to 10% of their earnings withheld, subject to certain maximums, to be used to purchase shares of the Company’s Class A Common Stock at certain purchase dates.

Share-based compensation expense was as follows for the periods indicated:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Cost of sales	$	193	$	471	$	(81)	$	1,175
Selling and marketing	2,393		2,499		7,021		5,978
Research and development	168		465		216		829
General and administrative	4,958		4,750		13,690		12,304
Total share-based compensation	$	7,712	$	8,185	$	20,846	$	20,286

As of September 30, 2024, total unrecognized compensation expense related to unvested share-based compensation totaled $38.2 million and is expected to be recognized over a weighted-average period of 1.8 years.